Company · CIK 0000704159 · SIC 2836 — Biological Products, (No Diagnostic Substances)
VBI VACCINES INC. · VBIV
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 6, 2016 PForm 4/A → | Mar 9, 2017, 1:36 pm EST | PERCEPTIVE ADVISORS LLC +210% Owner | 3,383,955 | $3.05 | $10,321,063 | 6,245,725 | +118% | plan? |
| Dec 6, 2016 PForm 4 → | Dec 8, 2:23 pm EST | PERCEPTIVE ADVISORS LLC +210% Owner | 3,383,955 | $3.05 | $10,321,063 | 6,213,314 | +120% | plan? amended |
| Aug 14, 2015 PForm 4 → | Aug 18, 6:45 am EDT | PERCEPTIVE ADVISORS LLC +210% Owner | 650,000 | $2.08 | $1,352,000 | 3,260,356 | +24.9% | plan? |
| Aug 13, 2015 AForm 4 → | Aug 17, 8:01 pm EDT | Steven GillisDirector, 10% Owner | 650,000 | $2.10 | $1,365,000 | 4,047,830 | — | plan? |
| Aug 13, 2015 AForm 4 → | Aug 17, 7:52 pm EDT | ARCH VENTURE FUND VI LP +510% Owner | 650,000 | $2.10 | $1,365,000 | 4,047,830 | — | plan? |
| Apr 8, 2015 JForm 4 → | Apr 10, 3:29 pm EDT | David Evander AndersonSenior VP, Researc | 46,731 | — | — | 86,787 | — | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 18, 2017 AForm 4 → | Apr 19, 8:56 pm EDT | Jeff BaxterCEO, President, Director | 20,000 | — | — | 20,000 | — | |
| Apr 17, 2017 AForm 4 → | Apr 19, 8:49 pm EDT | Michel DeWildeDirector | 12,500 | — | — | 12,500 | — | |
| Dec 6, 2016 PForm 4/A → | Mar 9, 2017, 1:36 pm EST | PERCEPTIVE ADVISORS LLC +210% Owner | 1,705,053 | $3.52 | $6,002,375 | 2,068,824 | — | |
| Dec 6, 2016 PForm 4 → | Dec 8, 2:23 pm EST | PERCEPTIVE ADVISORS LLC +210% Owner | 1,705,053 | $3.52 | $6,002,375 | 2,068,824 | — | amended |
| Jul 30, 2015 AForm 4 → | Aug 5, 5:50 pm EDT | Steven GillisDirector, 10% Owner | 70,000 | — | — | 191,089 | — | late |
| Jul 30, 2015 AForm 4 → | Aug 5, 5:50 pm EDT | Sam ChawlaDirector | 40,000 | — | — | 80,000 | — | late |
| Jul 30, 2015 AForm 4 → | Aug 5, 5:50 pm EDT | Michel DeWildeDirector | 40,000 | — | — | 80,000 | — | late |
| Jul 30, 2015 AForm 4 → | Aug 5, 5:49 pm EDT | Trent D DavisDirector | 40,000 | — | — | 80,000 | — | late |
| Jul 30, 2015 AForm 4 → | Aug 5, 5:49 pm EDT | Michael SteinmetzDirector | 40,000 | — | — | 80,000 | — | late |
| Jul 30, 2015 AForm 4 → | Aug 5, 5:49 pm EDT | Egidio NascimentoChief Financial Officer | 150,000 | — | — | 526,700 | — | late |
| Jul 30, 2015 AForm 4 → | Aug 5, 5:49 pm EDT | Alan P TimminsDirector | 40,000 | — | — | 80,000 | — | late |
| Jul 30, 2015 AForm 4 → | Aug 5, 5:49 pm EDT | David Evander AndersonChief Scientific Officer | 225,000 | — | — | 682,304 | — | late |
| Jul 30, 2015 AForm 4 → | Aug 5, 5:49 pm EDT | Jeff BaxterChief Executive Officer | 300,000 | — | — | 1,344,944 | — | late |
| Jul 30, 2015 AForm 4 → | Aug 5, 5:49 pm EDT | Marc KirchmeierVP, Vaccine Form Development | 100,000 | — | — | 367,793 | — | late |
| Jul 30, 2015 AForm 4 → | Aug 5, 5:48 pm EDT | T. Adam BuckleyVP, Business Development | 75,000 | — | — | 263,926 | — | late |
| Jul 25, 2014 AForm 4/A → | Apr 2, 2015, 2:46 pm EDT | Trent D DavisDirector | 40,000 | — | — | 40,000 | — |